- Home
- MARPS vs VRAX Comparison
MARPS vs VRAX Comparison
Compare MARPS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | VRAX |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 2.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MARPS | VRAX |
|---|---|---|
| Price | $4.37 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 5.9K | ★ 33.5K |
| Earning Date | 02-13-2026 | 06-12-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $0.10 |
| 52 Week High | $6.49 | $13.19 |
Technical Indicators
Market Signals| Indicator | MARPS | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 38.96 |
| Support Level | $4.17 | $0.18 |
| Resistance Level | $4.94 | $3.01 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 24.04 | 17.01 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.